MedTrace Logo

Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

NCT04393311 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-03-03

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and efficacy of intravenous (IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease severity, need for ventilator support, and mortality in patients with COVID 19.

Conditions

Interventions

DRUG

Ulinastatin

Ulinastatin administered via IV infusion (200,000/infusion)

DRUG

Placebo

Placebo to match ulinastatin administered via IV infusion

Sponsors & Collaborators

Principal Investigators

  • Kevin V Grimes, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2022-08-31
Completion
2022-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04393311 on ClinicalTrials.gov